Omnicare draws buyout interest from Express Scripts, CVS; Akorn asks Oklahoma not to use its drugs to execute;

@FiercePharma: From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets for Q1. Story | Follow @FiercePharma

@EricPFierce: Drug shortages become way for #Mylan to parry against #Teva but will the FTC care? More | Follow @EricPFierce

@CarlyHFierce: #ICYMI yesterday: Teva CEO 'takes the high road' to rebut Mylan chairman's attack. News | Follow @CarlyHFierce

> Akorn ($AKRX) has asked Oklahoma authorities not to use its products for executions. Story

> Omnicare ($OCR), a supplier of drugs to nursing homes, is drawing interest from potential buyers, including Express Scripts Holding ($ESRX) and CVS Health ($CVS). Story

> GlaxoSmithKline ($GSK) CEO Andrew Witty met with U.K. health officials to voice his concerns before the country finalized changes to its drug pricing system. Report

Medical Device News

@FierceMedDev: Medtronic to test renal denervation as treatment for atrial fibrillation. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Kaiser backs startup in $12.5M round to speed healthcare data integration. News | Follow @VarunSaxena2

@EmilyWFierce: Abbott grabs #FDA OK for early pregnancy blood test. FierceDiagnostics Story | Follow @EmilyWFierce

> Greatbatch spins off neurostimulation unit to speed up growth. Article.

> Ninox gets $10M Series B to get wearable sleep apnea device through regulators. More

Biotech News

@FierceBiotech: Gilead's 'open to suggestion' on its next big M&A splash. Articles | Follow @FierceBiotech

@JohnCFierce: T-Vec panel demonstrates just how accepting the FDA and its panels are when it comes to "meh" cancer drugs. | Follow @JohnCFierce

@DamianFierce: Shouts to the 19 $OPHT workers who won $58M on the New York lottery. Article | Follow @DamianFierce

> Biotech's boom spells a spike in R&D down payments. Article

> Collegium swings for a $75M IPO for its abuse-proof painkiller. More

And Finally... Subbing one serving per day of water or unsweetened tea or coffee for one serving of a sugar-sweetened soft drink or dairy beverage can significantly cut down the incidence of Type 2 diabetes, new research shows. More (sub. req.)

Suggested Articles

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.